Genmab
Update in progressGMAB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Genmab A/S is a Copenhagen-based biotechnology company that develops antibody-based therapies for cancer and other diseases. It markets Epkinly and Tepkinly for relapsed/refractory DLBCL, large B-cell lymphoma, and follicular lymphoma; Tivdak for recurrent/metastatic cervical cancer; and Darzalex/Darzalex Faspro, Rybrevant, Tecvayli, Talvey, Kesimpta, and Tepezza. It is building numerous candidates (Epcoritamab, tisotumab vedotin, Acasunlimab, GEN programs) and collaborates with AbbVie, Pfizer, BioNTech, J&J, and others. Founded 1998, based in Copenhagen.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.13
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationDenmark
- CEODr. Jan G.J. van de Winkel Ph.D.
- Founded1998
- Employees3,119
- Websitewww.genmab.com
Identifiers
- ISINUS3723032062
- FIGIBBG004MPKM64
- LEI529900MTJPDPE4MHJ122
- CUSIP372303206
- CIK0001434265